Literature DB >> 17437775

The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy.

Patrick Craig Walsh1.   

Abstract

PURPOSE: This review is of the events that led up to the discovery of the cavernous nerves and the development of nerve sparing radical retropubic prostatectomy.
MATERIALS AND METHODS: The correspondence between Pieter J. Donker and Patrick C. Walsh, along with the publication folders describing the anatomy of the dorsal vein complex, pelvic plexus and cavernous nerves, and pelvic fascia, are reviewed.
RESULTS: Serendipity had a major role in the fateful meeting of Pieter J. Donker and Patrick C. Walsh on February 13, 1981 when they dissected out the cavernous nerves in a stillborn male infant. During the next year intraoperative observations identified the capsular arteries and veins of the prostate as the likely microscopic landmark that could be used in the adult male pelvis to identify the microscopic cavernous nerves. Twenty-five years ago, on April 26, 1982, the first purposeful nerve sparing radical prostatectomy was performed. One year following surgery patient sexual function was normal, and 25 years later he has retained his quality of life and an undetectable prostate specific antigen.
CONCLUSIONS: The events that led up to the first nerve sparing radical prostatectomy illustrate the influence of serendipity on discovery.

Entities:  

Mesh:

Year:  2007        PMID: 17437775     DOI: 10.1016/j.juro.2007.01.012

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  31 in total

1.  Shared responsibility for treatment-related morbidity for prostate cancer.

Authors:  Joseph L Chin; Glenn Bauman
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

2.  A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment.

Authors:  Leslie R Schover; Andrea L Canada; Ying Yuan; Dawen Sui; Leah Neese; Rosell Jenkins; Michelle M Rhodes
Journal:  Cancer       Date:  2011-09-26       Impact factor: 6.860

Review 3.  Robot-assisted prostatectomy: the new standard of care.

Authors:  Gencay Hatiboglu; Dogu Teber; Markus Hohenfellner
Journal:  Langenbecks Arch Surg       Date:  2011-02-02       Impact factor: 3.445

4.  Optimizing sexual function outcomes after radical prostatectomy.

Authors:  Anthony J Bella; Tom F Lue
Journal:  Can Urol Assoc J       Date:  2009-02       Impact factor: 1.862

5.  [The early development of brachytherapy of the prostate: a study on technique application in the development of urology].

Authors:  F H Moll; T Halling; P Niehoff; R M Engel; J Leissner
Journal:  Urologe A       Date:  2013-03       Impact factor: 0.639

6.  Quality of life in men undergoing active surveillance for localized prostate cancer.

Authors:  Jonathan Bergman; Mark S Litwin
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

Review 7.  Landmarks in erectile function recovery after radical prostatectomy.

Authors:  Emmanuel Weyne; Fabio Castiglione; Frank Van der Aa; Trinity J Bivalacqua; Maarten Albersen
Journal:  Nat Rev Urol       Date:  2015-04-14       Impact factor: 14.432

8.  M1 Macrophages Are Predominantly Recruited to the Major Pelvic Ganglion of the Rat Following Cavernous Nerve Injury.

Authors:  Hotaka Matsui; Nikolai A Sopko; Johanna L Hannan; Allison A Reinhardt; Max Kates; Takahiro Yoshida; Xiaopu Liu; Fabio Castiglione; Petter Hedlund; Emmanuel Weyne; Maarten Albersen; Trinity J Bivalacqua
Journal:  J Sex Med       Date:  2017-02       Impact factor: 3.802

Review 9.  Erectile dysfunction following prostatectomy: prevention and treatment.

Authors:  Ahmed Magheli; Arthur L Burnett
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

Review 10.  Management of complications of prostate cancer treatment.

Authors:  M Dror Michaelson; Shane E Cotter; Patricio C Gargollo; Anthony L Zietman; Douglas M Dahl; Matthew R Smith
Journal:  CA Cancer J Clin       Date:  2008-05-23       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.